PMID- 17971662
OWN - NLM
STAT- MEDLINE
DCOM- 20080620
LR  - 20181201
IS  - 1421-9751 (Electronic)
IS  - 0008-6312 (Linking)
VI  - 110
IP  - 2
DP  - 2008
TI  - Periprocedural abciximab administration in ST elevation myocardial infarction 
      patients. Effect on severe microvascular obstruction beyond the restoration of 
      epicardial coronary flow by primary angioplasty.
PG  - 129-34
AB  - OBJECTIVES: The impact of periprocedural (before primary percutaneous coronary 
      angioplasty, PCI) abciximab administration on microvascular obstruction in 
      patients with occluded infarct-related artery (IRA) is unknown. METHODS: We 
      studied 36 consecutive patients with first ST elevation myocardial infarction 
      (STEMI) and occluded IRA treated with successful primary PCI within 12 h from 
      symptom onset, who received intravenous abciximab immediately before PCI and 49 
      matched patients who did not receive abciximab as controls. All patients 
      underwent delayed-enhanced magnetic resonance (DE-MR) 6 +/- 2 days after PCI. 
      Necrosis was judged as transmural when DE was extended to > or =75% of left 
      ventricular (LV) segment thickness. Severe microvascular obstruction was 
      identified as areas of late hypoenhancement surrounded by DE. RESULTS: Time to 
      treatment was comparable in the two groups (182 +/- 60 vs. 188 +/- 110 min, 
      respectively). Transmurality and severe microvascular obstruction were present in 
      3.03 +/- 2.8 versus 3.09 +/- 2.9 (p = 0.9) and 1.05 +/- 1.5 versus 1.06 +/- 1.8 
      (p = 0.6) of LV segments, respectively, in the abciximab group versus controls. 
      At multivariate analysis, severe microvascular obstruction was independently 
      associated only with transmural necrosis (OR 1.5, p < 0.001) and age (OR 1.1, p = 
      0.02) but not with the use of abciximab. CONCLUSIONS: Severe microvascular 
      obstruction after primary PCI of STEMI patients with occluded IRA is related to 
      transmural necrosis but not to the use of abciximab.
CI  - Copyright 2007 S. Karger AG, Basel.
FAU - Tarantini, Giuseppe
AU  - Tarantini G
AD  - Department of Cardiac, University of Padova, Padova, Italy. 
      giuseppe.tarantini.1@unipd.it
FAU - Ramondo, Angelo
AU  - Ramondo A
FAU - Corbetti, Francesco
AU  - Corbetti F
FAU - Perazzolo Marra, Martina
AU  - Perazzolo Marra M
FAU - Cacciavillani, Luisa
AU  - Cacciavillani L
FAU - Napodano, Massimo
AU  - Napodano M
FAU - Bilato, Claudio
AU  - Bilato C
FAU - Razzolini, Renato
AU  - Razzolini R
FAU - Iliceto, Sabino
AU  - Iliceto S
LA  - eng
PT  - Journal Article
DEP - 20071031
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Aged
MH  - *Angioplasty, Balloon, Coronary
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Coronary Angiography
MH  - Coronary Circulation/*drug effects
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*administration & dosage
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Myocardial Infarction/*therapy
MH  - Myocardium/pathology
MH  - Necrosis
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Time Factors
EDAT- 2007/11/01 09:00
MHDA- 2008/06/21 09:00
CRDT- 2007/11/01 09:00
PHST- 2007/03/15 00:00 [received]
PHST- 2007/06/17 00:00 [accepted]
PHST- 2007/11/01 09:00 [pubmed]
PHST- 2008/06/21 09:00 [medline]
PHST- 2007/11/01 09:00 [entrez]
AID - 000110492 [pii]
AID - 10.1159/000110492 [doi]
PST - ppublish
SO  - Cardiology. 2008;110(2):129-34. doi: 10.1159/000110492. Epub 2007 Oct 31.